Clinical Trial Update: Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy volunteers aged 2 years and older; study complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Pneumonia

Drugs mentioned

• 23-valent pneumococcal polysaccharide vaccine (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Conditions: Pneumonia, Pneumococcal | Phase 3 | Status: COMPLETED